ArticleACS omega2026
β‑Ecdysone-Loaded Gelatin Methacryloyl Hydrogel Accelerates Diabetic Wound Healing by Improving Angiogenesis.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Delayed diabetic wound healing is partly attributed to vascular endothelial cell dysfunction induced by persistent hyperglycemia. β-Ecdysone (β-E), a naturally occurring steroidal compound, has been reported to protect endothelial function and alleviate hyperglycemia. This study aimed to develop a β-E-loaded gelatin methacryloyl (GelMA) hydrogel and evaluate its potential as a dressing to promote diabetic wound healing. The effects of β-E on human umbilical vein endothelial cells (HUVECs) under high-glucose conditions were evaluated by assessing proliferation, migration, and angiogenic capacity in vitro, along with the physicochemical properties, biocompatibility, and bioactivity of the resulting β-E/GelMA hydrogel. The therapeutic efficacy of the β-E/GelMA hydrogel in promoting diabetic wound healing was systematically assessed in rodent models. The results showed that β-E at concentrations ranging from 5 to 640 μmol/L was noncytotoxic to HUVEC viability. Among the tested concentrations, 20 μmol/L β-E conferred the optimal enhancement of HUVEC proliferation, migration, and angiogenic capacity. The β-E/GelMA hydrogels achieved sustained β-E release in vitro and exhibited physicochemical properties, biocompatibility, and bioactivity comparable to those of unmodified GelMA hydrogels. In vivo, β-E/GelMA hydrogels could efficiently promote the closure of diabetic wounds in diabetic rats. Immunohistochemical staining for CD31 and α-SMA demonstrated that β-E/GelMA hydrogels significantly promoted neovascularization and vascular maturation in vivo. We conclude that the β-E/GelMA hydrogels could be developed as a novel wound dressing for diabetic wound treatment. Altogether, the findings of this study show that the β-E/GelMA hydrogels could be developed as a novel wound dressing for diabetic wound treatment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.